{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T07:03:50Z","timestamp":1791097430126,"version":"4.1.0"},"reference-count":30,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2000,5,1]],"date-time":"2000-05-01T00:00:00Z","timestamp":957139200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2000,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            <jats:italic>Pneumocystis carinii<\/jats:italic>\n            pneumonia remains one of the most serious complications of immunosuppressed patients. In this study, the in vitro pharmacodynamic parameters of four sordarin derivatives (GM 191519, GM 237354, GM 193663, and GM 219771) have been evaluated by a new quantitative approach and compared with the commercially available drugs pentamidine, atovaquone, and trimethoprim-sulfamethoxazole (TMP-SMX). In vitro activities and in vivo therapeutic efficacies of sordarin derivatives against\n            <jats:italic>P. carinii<\/jats:italic>\n            were also evaluated. In vitro activity was determined by the broth microdilution technique, comparing the total number of microorganisms in treated and drug-free cultures by using Giemsa staining. The in vitro maximum effect (\n            <jats:italic>E<\/jats:italic>\n            <jats:sub>max<\/jats:sub>\n            ), the drug concentrations to reach 50% of\n            <jats:italic>E<\/jats:italic>\n            <jats:sub>max<\/jats:sub>\n            (EC\n            <jats:sub>50<\/jats:sub>\n            ), and the slope of the dose-response curve were then estimated by the Hill equation (\n            <jats:italic>E<\/jats:italic>\n            <jats:sub>max<\/jats:sub>\n            sigmoid model). Sordarin derivatives were the most potent agents against\n            <jats:italic>P. carinii<\/jats:italic>\n            , with EC\n            <jats:sub>50<\/jats:sub>\n            s of 0.00025, 0.0007, 0.0043, and 0.025 \u03bcg\/ml for GM 191519, GM 237354, GM 193663, and GM 219771, respectively. The EC\n            <jats:sub>50<\/jats:sub>\n            s of pentamidine, atovaquone, and TMP-SMX were 0.025, 0.16, and 26.7\/133.5 \u03bcg\/ml, respectively. The results obtained with this approach showed GM 237354 and GM 191519 to be approximately 35- and 100-fold more active in vitro than pentamidine, the most active marketed compound. All sordarin derivatives tested were at least 5,000-fold more active in vitro than TMP-SMX. The three sordarin derivatives tested in vivo\u2014GM 191519, GM 237354, and GM 219771\u2014showed a marked therapeutic efficacy, defined as reduction of cyst forms per gram of lung. GM 191519 was the most potent (daily dose reducing 50% of the\n            <jats:italic>P. carinii<\/jats:italic>\n            burden in the lungs [ED\n            <jats:sub>50<\/jats:sub>\n            ], 0.05 mg\/kg\/day) followed by GM 237354 and GM 219771 (ED\n            <jats:sub>50<\/jats:sub>\n            s, 0.30 and 0.49 mg\/kg\/day, respectively). Good agreement between in vitro parameters and in vivo outcome was obtained when\n            <jats:italic>P. carinii<\/jats:italic>\n            pneumonia in rats was treated with sordarin derivatives.\n          <\/jats:p>","DOI":"10.1128\/aac.44.5.1284-1290.2000","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T09:56:57Z","timestamp":1027763817000},"page":"1284-1290","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":33,"title":["In Vitro Pharmacodynamic Parameters of Sordarin Derivatives in Comparison with Those of Marketed Compounds against\n            <i>Pneumocystis carinii<\/i>\n            Isolated from Rats"],"prefix":"10.1128","volume":"44","author":[{"given":"Pablo","family":"Aviles","sequence":"first","affiliation":[{"name":"<!--label omitted: 1-->Department of Chemotherapy, GlaxoWellcome, S.A., Madrid, Spain,1 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El-Moukhtar","family":"Aliouat","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Department of Chemotherapy, GlaxoWellcome, S.A., Madrid, Spain,1 and"},{"name":"<!--label omitted: 2-->Laboratoire de Parasitologie, Faculte\u0301 de Pharmacie,2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Martinez","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Department of Chemotherapy, GlaxoWellcome, S.A., Madrid, Spain,1 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Dei-Cas","sequence":"additional","affiliation":[{"name":"<!--label omitted: 3-->Faculte\u0301 de Me\u0301decine et Centre Hospitalier Regional Universitaire du Lille,3 and"},{"name":"<!--label omitted: 4-->Department of Microbiology of Ecosystems, Institut Pasteur de Lille,4 Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esperanza","family":"Herreros","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Department of Chemotherapy, GlaxoWellcome, S.A., Madrid, Spain,1 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucien","family":"Dujardin","sequence":"additional","affiliation":[{"name":"<!--label omitted: 4-->Department of Microbiology of Ecosystems, Institut Pasteur de Lille,4 Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domingo","family":"Gargallo-Viola","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Department of Chemotherapy, GlaxoWellcome, S.A., Madrid, Spain,1 and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1258\/002367794781065870","article-title":"Guidelines for the welfare of animals in rodent protection tests. A report from the rodent test working party.","volume":"28","author":"Acred P.","year":"1994","unstructured":"Acred P. Hennessey T. D. MacArthur-Clark J. A. Merrikin D. J. Ryan D. M. Smulders H. C. Troke P. F. Wilson R. G. Straughan D. W. Guidelines for the welfare of animals in rodent protection tests. A report from the rodent test working party. Lab. Anim. 28 1994 13 18","journal-title":"Lab. Anim."},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"41S","DOI":"10.1111\/j.1550-7408.1997.tb05765.x","article-title":"Development of Pneumocystis animal models: corticosteroid-treated Wistar rat; SCID mouse and Nude rat.","volume":"44","author":"Aliouat E. M.","year":"1997","unstructured":"Aliouat E. M. Martinez A. Jimenez E. Dei-Cas E. Mullet C. Delcourt P. Gargallo-Viola D. Development of Pneumocystis animal models: corticosteroid-treated Wistar rat; SCID mouse and Nude rat. J. Eukaryot. Microbiol. 44 1997 41S 42S","journal-title":"J. Eukaryot. Microbiol."},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0248-4900(05)80190-X","article-title":"In vitro attachment of Pneumocystis carinii from mouse and rat origin.","volume":"77","author":"Aliouat E. M.","year":"1993","unstructured":"Aliouat E. M. Dei-Cas E. Ouassi M. A. Palluault F. Soulez B. Camus D. In vitro attachment of Pneumocystis carinii from mouse and rat origin. Biol. Cell 77 1993 209 217","journal-title":"Biol. Cell"},{"key":"e_1_3_2_5_2","first-page":"94","article-title":"Intranasal inoculation of mouse, rat or rabbit-derived Pneumocystis in SCID mouse.","volume":"3","author":"Aliouat E. M.","year":"1993","unstructured":"Aliouat E. M. Mazars E. Dei-Cas E. Cesbron J. Y. Camus D. Intranasal inoculation of mouse, rat or rabbit-derived Pneumocystis in SCID mouse. J. Protozool. Res. 3 1993 94 98","journal-title":"J. Protozool. Res."},{"key":"e_1_3_2_6_2","first-page":"116S","article-title":"Pneumocystis carinii growth kinetics in culture systems and in hosts: involvement of each life cycle parasite stage.","volume":"46","author":"Aliouat E. M.","year":"1999","unstructured":"Aliouat E. M. Dujardin L. Martinez A. Duriez T. Dei-Cas E. Pneumocystis carinii growth kinetics in culture systems and in hosts: involvement of each life cycle parasite stage. J. Eukaryot. Microbiol. 46 1999 116S 117S","journal-title":"J. Eukaryot. Microbiol."},{"key":"e_1_3_2_7_2","unstructured":"Amsterdam\n              D.\n          Susceptibility testing of antimicrobials in liquid media\n          Antibiotics in laboratory medicine\n          3rd ed.\n              Lorian\n              V.\n          1991\n          53\n          105\n          Williams & Wilkins Ltd.\n          Baltimore Md"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/BF01964463","article-title":"Models for evaluating compounds for activity against Pneumocystis carinii.","volume":"10","author":"Barlett M. S.","year":"1991","unstructured":"Barlett M. S. Models for evaluating compounds for activity against Pneumocystis carinii. Eur. J. Clin. Microbiol. Infect. Dis. 10 1991 199 201","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/jac\/39.1.45","article-title":"In vitro activity of atovaquone, sulfamethoxazole and dapsone alone and combined with inhibitors of dihydrofolate reductase and macrolides against Pneumocystis carinii.","volume":"39","author":"Cirioni O.","year":"1997","unstructured":"Cirioni O. Giacometti A. Scalise G. In vitro activity of atovaquone, sulfamethoxazole and dapsone alone and combined with inhibitors of dihydrofolate reductase and macrolides against Pneumocystis carinii. J. Antimicrob. Chemother. 39 1997 45 51","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_10_2","unstructured":"Craig\n              W. A.\n              Suh\n              B.\n          Protein binding and the antimicrobial effects: methods for the determination of protein binding\n          Antibiotics in laboratory medicine\n          3rd ed.\n              Lorian\n              V.\n          1991\n          367\n          402\n          Williams & Wilkins Ltd.\n          Baltimore Md"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1550-7408.1989.tb02691.x","article-title":"In vitro studies of Pneumocystis carinii.","volume":"36","author":"Cushion M. T.","year":"1989","unstructured":"Cushion M. T. In vitro studies of Pneumocystis carinii. J. Protozool. 36 1989 45 52","journal-title":"J. Protozool."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.9.2274"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.32.3.289"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.11.2863"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1550-7408.1997.tb05766.x"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.6.1225"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.5.2402"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.4.733"},{"key":"e_1_3_2_19_2","unstructured":"National Committee for Clinical Laboratory Standards\n          Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically\n          2nd ed.\n          1990 Approved standard M7-A2 10. National Committee for Clinical Laboratory Standards Villanova Pa."},{"key":"e_1_3_2_20_2","unstructured":"National Committee for Clinical Laboratory Standards\n          Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A.\n          1997\n          National Committee for Clinical Laboratory Standards\n          Villanova Pa"},{"key":"e_1_3_2_21_2","unstructured":"National Committee for Clinical Laboratory Standards\n          Methodology for the serum bactericidal test. Approved guideline M21-A.\n          1999\n          National Committee for Clinical Laboratory Standards\n          Villanova Pa"},{"key":"e_1_3_2_22_2","unstructured":"National Committee for Clinical Laboratory Standards\n          Methods for determining bactericidal activity of antimicrobial agents. Approved guideline M26-A.\n          1999\n          National Committee for Clinical Laboratory Standards\n          Villanova Pa"},{"key":"e_1_3_2_23_2","first-page":"109","article-title":"Effect of sex and dexamethasone dose on the experimental host for Pneumocystis carinii.","volume":"46","author":"Oz H. S.","year":"1996","unstructured":"Oz H. S. Hughes W. T. Effect of sex and dexamethasone dose on the experimental host for Pneumocystis carinii. Lab. Anim. Sci. 46 1996 109 110","journal-title":"Lab. Anim. Sci."},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1128\/AAC.24.5.674","article-title":"Biological profile and response to anti-Pneumocystis agents of Pneumocystis carinii in cell culture.","volume":"24","author":"Pifer L. L.","year":"1983","unstructured":"Pifer L. L. Pifer D. D. Woods D. R. Biological profile and response to anti-Pneumocystis agents of Pneumocystis carinii in cell culture. Antimicrob. Agents Chemother. 24 1983 673 678","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_2_25_2","first-page":"151S","article-title":"Treatment and prevention of Pneumocystis carinii pneumonia and further elucidation of the P. carinii life cycle with 1,3-beta-glucan synthesis inhibitor L-671,329.","volume":"38","author":"Schmatz D. M.","year":"1991","unstructured":"Schmatz D. M. Powles M. McFadden D. C. Pittarelli L. A. Liberator P. A. Anderson J. W. Treatment and prevention of Pneumocystis carinii pneumonia and further elucidation of the P. carinii life cycle with 1,3-beta-glucan synthesis inhibitor L-671,329. J. Protozool. 38 1991 151S 153S","journal-title":"J. Protozool."},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1550-7408.1993.tb04902.x","article-title":"The challenge of Pneumocystis carinii culture.","volume":"40","author":"Sloand E.","year":"1993","unstructured":"Sloand E. Laughon B. Armstrong M. Bartlett M. S. Blumenfeld W. Cushion M. T. Kalica A. Kovacs J. A. Martin W. Pitt E. Pesanti E. L. Richards F. Rose R. Walzer P. The challenge of Pneumocystis carinii culture. J. Eukaryot. Microbiol. 40 1993 188 195","journal-title":"J. Eukaryot. Microbiol."},{"key":"e_1_3_2_27_2","unstructured":"Smith\n              J. W.\n              Bartlett\n              M. S.\n              Queener\n              S. F.\n          Development of models and their use to discover new drugs for therapy and prophylaxis of Pneumocystis carinii pneumonia.\n          Pneumocystis carinii pneumonia.\n              Walzer\n              P. D.\n          1994\n          Marcell Decker Inc.\n          New York N.Y"},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1051\/parasite\/19886315","article-title":"Le lapin, h\u00f4te experimental de Pneumocystis carinii.","volume":"63","author":"Soulez B.","year":"1988","unstructured":"Soulez B. Dei-Cas E. Camus D. Le lapin, h\u00f4te experimental de Pneumocystis carinii. Ann. Parasitol. Hum. Comp. 63 1988 5 15","journal-title":"Ann. Parasitol. Hum. Comp."},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.2307\/3283134"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.9.4.489"},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1042\/cs0590311","article-title":"The modeling of drug response.","volume":"59","author":"Whiting B.","year":"1980","unstructured":"Whiting B. Gilman A. G. The modeling of drug response. Clin. Sci. 59 1980 311 315","journal-title":"Clin. Sci."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.44.5.1284-1290.2000","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.44.5.1284-1290.2000","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T16:54:16Z","timestamp":1645462456000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.44.5.1284-1290.2000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,5]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2000,5]]}},"alternative-id":["10.1128\/AAC.44.5.1284-1290.2000"],"URL":"https:\/\/doi.org\/10.1128\/aac.44.5.1284-1290.2000","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,5]]},"assertion":[{"value":"1999-07-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2000-01-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2000-05-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}